Your browser doesn't support javascript.
loading
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Ben-Ami, E; Barysauskas, C M; von Mehren, M; Heinrich, M C; Corless, C L; Butrynski, J E; Morgan, J A; Wagner, A J; Choy, E; Yap, J T; Van den Abbeele, A D; Solomon, S M; Fletcher, J A; Demetri, G D; George, S.
Afiliación
  • Ben-Ami E; Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, Boston.
  • Barysauskas CM; Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston.
  • von Mehren M; Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia.
  • Heinrich MC; VA Portland Health Care System and Oregon Health and Science University, Portland.
  • Corless CL; Oregon Health and Science University, Portland.
  • Butrynski JE; Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, Boston.
  • Morgan JA; Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, Boston.
  • Wagner AJ; Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, Boston.
  • Choy E; Division of Hematology Oncology, Massachusetts General Hospital, Boston.
  • Yap JT; Huntsman Cancer Institute, University of Utah, Salt Lake City Department of Radiology, University of Utah, Salt Lake City.
  • Van den Abbeele AD; Department of Imaging, Dana Farber Cancer Institute, Boston Department of Radiology.
  • Solomon SM; Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, Boston.
  • Fletcher JA; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston.
  • Demetri GD; Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, Boston Department of Ludwig Center at Dana Farber/Harvard Cancer Center and Harvard Medical School, Boston, USA.
  • George S; Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, Boston suzanne_george@dfci.harvard.edu.
Ann Oncol ; 27(9): 1794-9, 2016 09.
Article en En | MEDLINE | ID: mdl-27371698
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos de Fenilurea / Piridinas / Proteínas Proto-Oncogénicas c-kit / Resistencia a Antineoplásicos / Tumores del Estroma Gastrointestinal Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos de Fenilurea / Piridinas / Proteínas Proto-Oncogénicas c-kit / Resistencia a Antineoplásicos / Tumores del Estroma Gastrointestinal Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article Pais de publicación: Reino Unido